22.01.2010 • News

Abbott to Buy Starlims Technologies for $123 Million

Abbott Laboratories said it has agreed to acquire Israel-based Starlims Technologies for $123 million to boost its position in the global diagnostics market. The acquisition will give Abbott Starlims' advanced web-based applications to help laboratories store, retrieve and analyze clinical, managerial and administrative data, the company said. The Starlims line "will provide Abbott with leading products to build upon existing technologies and expertise in the emerging field of healthcare informatics," Edward Michael, Abbott's executive vice president for diagnostics products, said in a statement. Illinois-based Abbott said it expects the transaction to close in the first quarter of 2010 and that it will not impact its 2009 earnings forecast.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.